Cargando…
Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset
BACKGROUND: RNA vaccines against coronavirus disease 2019 (COVID-19) have demonstrated ∼95% efficacy in phase III clinical trials. Although complete vaccination consisted of 2 doses, the onset of protection for both licensed RNA vaccines was observed as early as 12 days after a single dose. The adap...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8030737/ https://www.ncbi.nlm.nih.gov/pubmed/33851143 http://dx.doi.org/10.1016/j.medj.2021.04.003 |
_version_ | 1783676127434244096 |
---|---|
author | Kalimuddin, Shirin Tham, Christine Y.L. Qui, Martin de Alwis, Ruklanthi Sim, Jean X.Y. Lim, Joey M.E. Tan, Hwee-Cheng Syenina, Ayesa Zhang, Summer L. Le Bert, Nina Tan, Anthony T. Leong, Yan Shan Yee, Jia Xin Ong, Eugenia Z. Ooi, Eng Eong Bertoletti, Antonio Low, Jenny G. |
author_facet | Kalimuddin, Shirin Tham, Christine Y.L. Qui, Martin de Alwis, Ruklanthi Sim, Jean X.Y. Lim, Joey M.E. Tan, Hwee-Cheng Syenina, Ayesa Zhang, Summer L. Le Bert, Nina Tan, Anthony T. Leong, Yan Shan Yee, Jia Xin Ong, Eugenia Z. Ooi, Eng Eong Bertoletti, Antonio Low, Jenny G. |
author_sort | Kalimuddin, Shirin |
collection | PubMed |
description | BACKGROUND: RNA vaccines against coronavirus disease 2019 (COVID-19) have demonstrated ∼95% efficacy in phase III clinical trials. Although complete vaccination consisted of 2 doses, the onset of protection for both licensed RNA vaccines was observed as early as 12 days after a single dose. The adaptive immune response that coincides with this onset of protection could represent the necessary elements of immunity against COVID-19. METHODS: Serological and T cell analysis was performed in a cohort of 20 healthcare workers after receiving the first dose of the Pfizer/BioNTech BNT162b2 vaccine. The primary endpoint was the adaptive immune responses detectable at days 7 and 10 after dosing. FINDINGS: Spike-specific T cells and binding antibodies were detectable 10 days after the first dose of the vaccine, in contrast to receptor-blocking and severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) neutralizing antibodies, which were mostly undetectable at this early time point. CONCLUSIONS: Our findings suggest that early T cell and binding antibody responses, rather than either receptor-blocking or virus neutralizing activity, induced early protection against COVID-19. FUNDING: The study was funded by a generous donation from The Hour Glass to support COVID-19 research. |
format | Online Article Text |
id | pubmed-8030737 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Author(s). Published by Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80307372021-04-09 Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset Kalimuddin, Shirin Tham, Christine Y.L. Qui, Martin de Alwis, Ruklanthi Sim, Jean X.Y. Lim, Joey M.E. Tan, Hwee-Cheng Syenina, Ayesa Zhang, Summer L. Le Bert, Nina Tan, Anthony T. Leong, Yan Shan Yee, Jia Xin Ong, Eugenia Z. Ooi, Eng Eong Bertoletti, Antonio Low, Jenny G. Med (N Y) Case Report BACKGROUND: RNA vaccines against coronavirus disease 2019 (COVID-19) have demonstrated ∼95% efficacy in phase III clinical trials. Although complete vaccination consisted of 2 doses, the onset of protection for both licensed RNA vaccines was observed as early as 12 days after a single dose. The adaptive immune response that coincides with this onset of protection could represent the necessary elements of immunity against COVID-19. METHODS: Serological and T cell analysis was performed in a cohort of 20 healthcare workers after receiving the first dose of the Pfizer/BioNTech BNT162b2 vaccine. The primary endpoint was the adaptive immune responses detectable at days 7 and 10 after dosing. FINDINGS: Spike-specific T cells and binding antibodies were detectable 10 days after the first dose of the vaccine, in contrast to receptor-blocking and severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) neutralizing antibodies, which were mostly undetectable at this early time point. CONCLUSIONS: Our findings suggest that early T cell and binding antibody responses, rather than either receptor-blocking or virus neutralizing activity, induced early protection against COVID-19. FUNDING: The study was funded by a generous donation from The Hour Glass to support COVID-19 research. The Author(s). Published by Elsevier Inc. 2021-06-11 2021-04-08 /pmc/articles/PMC8030737/ /pubmed/33851143 http://dx.doi.org/10.1016/j.medj.2021.04.003 Text en © 2021 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Case Report Kalimuddin, Shirin Tham, Christine Y.L. Qui, Martin de Alwis, Ruklanthi Sim, Jean X.Y. Lim, Joey M.E. Tan, Hwee-Cheng Syenina, Ayesa Zhang, Summer L. Le Bert, Nina Tan, Anthony T. Leong, Yan Shan Yee, Jia Xin Ong, Eugenia Z. Ooi, Eng Eong Bertoletti, Antonio Low, Jenny G. Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset |
title | Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset |
title_full | Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset |
title_fullStr | Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset |
title_full_unstemmed | Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset |
title_short | Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset |
title_sort | early t cell and binding antibody responses are associated with covid-19 rna vaccine efficacy onset |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8030737/ https://www.ncbi.nlm.nih.gov/pubmed/33851143 http://dx.doi.org/10.1016/j.medj.2021.04.003 |
work_keys_str_mv | AT kalimuddinshirin earlytcellandbindingantibodyresponsesareassociatedwithcovid19rnavaccineefficacyonset AT thamchristineyl earlytcellandbindingantibodyresponsesareassociatedwithcovid19rnavaccineefficacyonset AT quimartin earlytcellandbindingantibodyresponsesareassociatedwithcovid19rnavaccineefficacyonset AT dealwisruklanthi earlytcellandbindingantibodyresponsesareassociatedwithcovid19rnavaccineefficacyonset AT simjeanxy earlytcellandbindingantibodyresponsesareassociatedwithcovid19rnavaccineefficacyonset AT limjoeyme earlytcellandbindingantibodyresponsesareassociatedwithcovid19rnavaccineefficacyonset AT tanhweecheng earlytcellandbindingantibodyresponsesareassociatedwithcovid19rnavaccineefficacyonset AT syeninaayesa earlytcellandbindingantibodyresponsesareassociatedwithcovid19rnavaccineefficacyonset AT zhangsummerl earlytcellandbindingantibodyresponsesareassociatedwithcovid19rnavaccineefficacyonset AT lebertnina earlytcellandbindingantibodyresponsesareassociatedwithcovid19rnavaccineefficacyonset AT tananthonyt earlytcellandbindingantibodyresponsesareassociatedwithcovid19rnavaccineefficacyonset AT leongyanshan earlytcellandbindingantibodyresponsesareassociatedwithcovid19rnavaccineefficacyonset AT yeejiaxin earlytcellandbindingantibodyresponsesareassociatedwithcovid19rnavaccineefficacyonset AT ongeugeniaz earlytcellandbindingantibodyresponsesareassociatedwithcovid19rnavaccineefficacyonset AT ooiengeong earlytcellandbindingantibodyresponsesareassociatedwithcovid19rnavaccineefficacyonset AT bertolettiantonio earlytcellandbindingantibodyresponsesareassociatedwithcovid19rnavaccineefficacyonset AT lowjennyg earlytcellandbindingantibodyresponsesareassociatedwithcovid19rnavaccineefficacyonset |